BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 31157663)

  • 1. The benefit of immediate compared with deferred antiretroviral therapy on CD4+ cell count recovery in early HIV infection.
    Sharma S; Schlusser KE; de la Torre P; Tambussi G; Draenert R; Pinto AN; Metcalf JA; Neaton JD; Laeyendecker O;
    AIDS; 2019 Jul; 33(8):1335-1344. PubMed ID: 31157663
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Which HIV-infected adults with high CD4 T-cell counts benefit most from immediate initiation of antiretroviral therapy? A post-hoc subgroup analysis of the START trial.
    Molina JM; Grund B; Gordin F; Williams I; Schechter M; Losso M; Law M; Ekong E; Mwelase N; Skoutelis A; Wiselka MJ; Vandekerckhove L; Benfield T; Munroe D; Lundgren JD; Neaton JD;
    Lancet HIV; 2018 Apr; 5(4):e172-e180. PubMed ID: 29352723
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved quality of life with immediate versus deferred initiation of antiretroviral therapy in early asymptomatic HIV infection.
    Lifson AR; Grund B; Gardner EM; Kaplan R; Denning E; Engen N; Carey CL; Chen F; Dao S; Florence E; Sanz J; Emery S;
    AIDS; 2017 Apr; 31(7):953-963. PubMed ID: 28121710
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of immediate initiation of antiretroviral therapy on risk of severe bacterial infections in HIV-positive people with CD4 cell counts of more than 500 cells per μL: secondary outcome results from a randomised controlled trial.
    O'Connor J; Vjecha MJ; Phillips AN; Angus B; Cooper D; Grinsztejn B; Lopardo G; Das S; Wood R; Wilkin A; Klinker H; Kantipong P; Klingman KL; Jilich D; Herieka E; Denning E; Abubakar I; Gordin F; Lundgren JD;
    Lancet HIV; 2017 Mar; 4(3):e105-e112. PubMed ID: 28063815
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pulmonary effects of immediate versus deferred antiretroviral therapy in HIV-positive individuals: a nested substudy within the multicentre, international, randomised, controlled Strategic Timing of Antiretroviral Treatment (START) trial.
    Kunisaki KM; Niewoehner DE; Collins G; Aagaard B; Atako NB; Bakowska E; Clarke A; Corbelli GM; Ekong E; Emery S; Finley EB; Florence E; Infante RM; Kityo CM; Madero JS; Nixon DE; Tedaldi E; Vestbo J; Wood R; Connett JE;
    Lancet Respir Med; 2016 Dec; 4(12):980-989. PubMed ID: 27773665
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The per-protocol effect of immediate versus deferred antiretroviral therapy initiation.
    Lodi S; Sharma S; Lundgren JD; Phillips AN; Cole SR; Logan R; Agan BK; Babiker A; Klinker H; Chu H; Law M; Neaton JD; Hernán MA;
    AIDS; 2016 Nov; 30(17):2659-2663. PubMed ID: 27782964
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.
    ; Danel C; Moh R; Gabillard D; Badje A; Le Carrou J; Ouassa T; Ouattara E; Anzian A; Ntakpé JB; Minga A; Kouame GM; Bouhoussou F; Emieme A; Kouamé A; Inwoley A; Toni TD; Ahiboh H; Kabran M; Rabe C; Sidibé B; Nzunetu G; Konan R; Gnokoro J; Gouesse P; Messou E; Dohoun L; Kamagate S; Yao A; Amon S; Kouame AB; Koua A; Kouamé E; Ndri Y; Ba-Gomis O; Daligou M; Ackoundzé S; Hawerlander D; Ani A; Dembélé F; Koné F; Guéhi C; Kanga C; Koule S; Séri J; Oyebi M; Mbakop N; Makaila O; Babatunde C; Babatounde N; Bleoué G; Tchoutedjem M; Kouadio AC; Sena G; Yededji SY; Assi R; Bakayoko A; Mahassadi A; Attia A; Oussou A; Mobio M; Bamba D; Koman M; Horo A; Deschamps N; Chenal H; Sassan-Morokro M; Konate S; Aka K; Aoussi E; Journot V; Nchot C; Karcher S; Chaix ML; Rouzioux C; Sow PS; Perronne C; Girard PM; Menan H; Bissagnene E; Kadio A; Ettiegne-Traore V; Moh-Semdé C; Kouame A; Massumbuko JM; Chêne G; Dosso M; Domoua SK; N'Dri-Yoman T; Salamon R; Eholié SP; Anglaret X
    N Engl J Med; 2015 Aug; 373(9):808-22. PubMed ID: 26193126
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of lifelong cumulative HIV viremia on long-term recovery of CD4+ cell count and CD4+/CD8+ ratio among patients on combination antiretroviral therapy.
    Seng R; Goujard C; Krastinova E; Miailhes P; Orr S; Molina JM; Saada M; Piroth L; Rouzioux C; Meyer L;
    AIDS; 2015 Mar; 29(5):595-607. PubMed ID: 25715104
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early time-limited antiretroviral therapy versus deferred therapy in South African infants infected with HIV: results from the children with HIV early antiretroviral (CHER) randomised trial.
    Cotton MF; Violari A; Otwombe K; Panchia R; Dobbels E; Rabie H; Josipovic D; Liberty A; Lazarus E; Innes S; van Rensburg AJ; Pelser W; Truter H; Madhi SA; Handelsman E; Jean-Philippe P; McIntyre JA; Gibb DM; Babiker AG;
    Lancet; 2013 Nov; 382(9904):1555-63. PubMed ID: 24209829
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative effectiveness of immediate antiretroviral therapy versus CD4-based initiation in HIV-positive individuals in high-income countries: observational cohort study.
    Lodi S; Phillips A; Logan R; Olson A; Costagliola D; Abgrall S; van Sighem A; Reiss P; Miró JM; Ferrer E; Justice A; Gandhi N; Bucher HC; Furrer H; Moreno S; Monge S; Touloumi G; Pantazis N; Sterne J; Young JG; Meyer L; Seng R; Dabis F; Vandehende MA; Pérez-Hoyos S; Jarrín I; Jose S; Sabin C; Hernán MA;
    Lancet HIV; 2015 Aug; 2(8):e335-43. PubMed ID: 26423376
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immediate Initiation of Antiretroviral Therapy for HIV Infection Accelerates Bone Loss Relative to Deferring Therapy: Findings from the START Bone Mineral Density Substudy, a Randomized Trial.
    Hoy JF; Grund B; Roediger M; Schwartz AV; Shepherd J; Avihingsanon A; Badal-Faesen S; de Wit S; Jacoby S; La Rosa A; Pujari S; Schechter M; White D; Engen NW; Ensrud K; Aagaard PD; Carr A;
    J Bone Miner Res; 2017 Sep; 32(9):1945-1955. PubMed ID: 28650589
    [TBL] [Abstract][Full Text] [Related]  

  • 12. No neurocognitive advantage for immediate antiretroviral treatment in adults with greater than 500 CD4+ T-cell counts.
    Wright EJ; Grund B; Robertson KR; Cysique L; Brew BJ; Collins GL; Poehlman-Roediger M; Vjecha MJ; Penalva de Oliveira AC; Standridge B; Carey C; Avihingsanon A; Florence E; Lundgren JD; Arenas-Pinto A; Mueller NJ; Winston A; Nsubuga MS; Lal L; Price RW;
    AIDS; 2018 May; 32(8):985-997. PubMed ID: 29424786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early Initiation Rather Than Prolonged Duration of Antiretroviral Therapy in HIV Infection Contributes to the Normalization of CD8 T-Cell Counts.
    Cao W; Mehraj V; Trottier B; Baril JG; Leblanc R; Lebouche B; Cox J; Tremblay C; Lu W; Singer J; Li T; Routy JP; ; Vézina S; Charest L; Milne M; Huchet E; Lavoie S; Friedman J; Duchastel M; Villielm F; Côté P; Potter M; Lessard B; Charron MA; Dufresne S; Turgeon ME; Rouleau D; Labrecque L; Fortin C; de Pokomandy A; Hal-Gagné V; Munoz M; Deligne B; Martel-Laferrière V; Gilmore N; Fletcher M; Szabo J
    Clin Infect Dis; 2016 Jan; 62(2):250-257. PubMed ID: 26349551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD4+ cell count recovery after combined antiretroviral therapy in the modern combined antiretroviral therapy era.
    Roul H; Mary-Krause M; Ghosn J; Delaugerre C; Pialoux G; Cuzin L; Launay O; Lacombe JM; Menard A; De Truchis P; Delfraissy JF; Weiss L; Costagliola D;
    AIDS; 2018 Nov; 32(17):2605-2614. PubMed ID: 30289817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies.
    ; Sterne JA; May M; Costagliola D; de Wolf F; Phillips AN; Harris R; Funk MJ; Geskus RB; Gill J; Dabis F; Miró JM; Justice AC; Ledergerber B; Fätkenheuer G; Hogg RS; Monforte AD; Saag M; Smith C; Staszewski S; Egger M; Cole SR
    Lancet; 2009 Apr; 373(9672):1352-63. PubMed ID: 19361855
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The rate of bone loss slows after 1-2 years of initial antiretroviral therapy: final results of the Strategic Timing of Antiretroviral Therapy (START) bone mineral density substudy.
    Carr A; Grund B; Schwartz AV; Avihingsanon A; Badal-Faesen S; Bernadino JI; Estrada V; La Rosa A; Mallon P; Pujari S; White D; Wyman Engen N; Ensrud K; Hoy JF;
    HIV Med; 2020 Jan; 21(1):64-70. PubMed ID: 31642586
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Demographic and HIV-specific characteristics of participants enrolled in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial.
    Sharma S; Babiker AG; Emery S; Gordin FM; Lundgren JD; Neaton JN; Bakowska E; Schechter M; Wiselka MJ; Wolff MJ;
    HIV Med; 2015 Apr; 16 Suppl 1(0 1):30-6. PubMed ID: 25711321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of micronutrient supplementation on disease progression in asymptomatic, antiretroviral-naive, HIV-infected adults in Botswana: a randomized clinical trial.
    Baum MK; Campa A; Lai S; Sales Martinez S; Tsalaile L; Burns P; Farahani M; Li Y; van Widenfelt E; Page JB; Bussmann H; Fawzi WW; Moyo S; Makhema J; Thior I; Essex M; Marlink R
    JAMA; 2013 Nov; 310(20):2154-63. PubMed ID: 24281460
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Virological remission after antiretroviral therapy interruption in female African HIV seroconverters.
    Gossez M; Martin GE; Pace M; Ramjee G; Premraj A; Kaleebu P; Rees H; Inshaw J; Stöhr W; Meyerowitz J; Hopkins E; Jones M; Hurst J; Porter K; Babiker A; Fidler S; Frater J;
    AIDS; 2019 Feb; 33(2):185-197. PubMed ID: 30325764
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suboptimal immune recovery during antiretroviral therapy with sustained HIV suppression in sub-Saharan Africa.
    Kroeze S; Ondoa P; Kityo CM; Siwale M; Akanmu S; Wellington M; de Jager M; Ive P; Mandaliya K; Stevens W; Boender TS; de Pundert ME; Sigaloff KCE; Reiss P; Wit FWNM; Rinke de Wit TF; Hamers RL
    AIDS; 2018 May; 32(8):1043-1051. PubMed ID: 29547445
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.